Click on the map for a list of participating countries.
An international comparative effectiveness study
The purpose of ISCHEMIA is to determine the best way to manage stable ischemic heart disease
Patients with moderate or severe ischemia on stress test imaging may be eligible for participation
If you are a physician and would like more information, please visit the For Physicians section. If you are a patient and would like to learn more about the ISCHEMIA study, please e-mail email@example.com
Drs. George Dangas, Judith Hochman, and Gregg Stone discuss the ISCHEMIA Trial and why every interventionalist should actively participate.
Ischemic heart disease (IHD) is
the leading cause of death and disability worldwide and affects 17,600,000
Americans, resulting in about 450,000 deaths in the United States annually.
Globally, 7.2 million deaths are caused by IHD each year.
therapy (medication and lifestyle changes) should always be used to treat
IHD. Many doctors routinely use an invasive approach in addition to
medical therapy to treat IHD; however, it is not known if this approach is
better than medical therapy alone as the initial treatment of patients
with stable ischemic heart disease (SIHD). ISCHEMIA is designed to find the
answer. Click here to learn more about the ISCHEMIA study.
Join us for our monthly study coordinator webinar the last Thursday of each month! Contact the ISCHEMIA CCC for details.
Congratulations to our top randomizing sites!
- Northwick Park Hospital (Middlesex, United Kingdom): Dr. Roxy Senior, Dr. Elghamaz & SCs Grace Young, Raisa Kavalakkat, Christopher Kinsey and Sothinathan Gurunathan (34 + 3 pending)
- Montreal Heart Institute (Montreal, Canada): Dr. Gilbert Gosselin, Dr. Patrick Garceau & SCs Rima Amche, Magalie Corfias & Nathalie St. Jean (23 + 2 pending)
- Centre Hospitalier Regional de Trois-Rivieres (Trois-Rivieres, Canada): Dr. Ariel Diaz, Dr. Gilbert Gosselin & SC Isabelle Roy (22)
- Coronary and Structural Heart Diseases Department, Institute of Cardiology (Warsaw, Poland): Dr. Marcin Demkow & Dr. Radek Pracon (20)
- University Hospital (London, Canada): Dr. Dennis Humen, William Kostuk & SC Sandy Carr (18)
- Ospedali Riuniti of Ancona (Ancona, Italy): Dr. Gian Perna, Dr. Alberta Pangrazi & SCs Marco Mazzanti & Francesa Pietrucci (15)
- CSS du Sud de Lanaudiere (Terrebonne, Canada):
Dr. Denis Phaneuf, Dr. Gilbert Gosselin & SCs Margaux David &
Mijanou Delorme (12)
- Hospital Universitario La Paz (Madrid, Spain): Dr. Jose Luis Lopez Sendon & SCs Almudena Castro & Silvia Valbuena (11)
- V.A. North Texas Health Care System (Dallas, USA): Dr. Subhash Banerjee, Dr. Sivavasavi Dinakaran & SCs Atif Mohammad & Preeti Kamath (10 + 1 pending)
- Vilnius University Hospital Santariskes Clinic (Vilnius, Lithuania): Dr. Aleksandras Laucevicius & SCs Irina Alitoit, Jelena Celutkiene & Denis Kablucko (10)
As of March 6th, there are 566 participants randomized across Argentina, Austria, Belgium, Canada, China, France, Germany, Hungary, India, Israel, Italy, Japan, Lithuania, Macedonia, Mexico, New Zealand, Poland, Russia, Serbia, Singapore, Spain, Sweden, Switzerland, the United Kingdom and the United States. In addition, there are sites in Australia and Saudi Arabia open for enrollment.